Zeposia® (ozanimod) – New drug approval
March 26, 2020 - Bristol-Myers Squibb announced the FDA approval of Zeposia (ozanimod), for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Top